cancer cells

The article discusses the role of optimism in scientific success, citing the author's personal experience of overcoming experimental failures in grad school. It highlights recent breakthroughs in 2026 but questions why many scientists are now losing hope despite these advancements.

Scientists have discovered that the MYC protein helps cancer cells survive chemotherapy by repairing damaged DNA. This protein rushes to broken DNA and recruits repair machinery, allowing tumors to recover from treatments. The finding sheds light on why some cancers are resistant to chemotherapy.

Scientists have discovered that vitamin B2 may help cancer cells survive by supporting a cellular shield that protects tumors from ferroptosis. Researchers used a vitamin B2-like compound to break down this protection and trigger cancer cell death in lab tests. This finding highlights a potential dark side to vitamin B2.

Researchers have developed a quantum 'thermometer' to measure temperatures inside living cancer cells, finding variations of up to 1 ºC between different cell parts. The technology uses nanosensors and was published in Nature. This breakthrough could lead to better understanding and treatment of cancer.

A study published in Nature on April 24, 2026, found that non-beating hearts in mice were rapidly overtaken by cancer cells, suggesting heartbeats may help prevent cancer. Additional findings include evidence that large octopuses dominated ancient seas and geopolitical factors influencing health data sets.

A study published in Nature on April 23, 2026, reveals that the mechanical pressure generated by the heart's pumping action inhibits cancer cell proliferation in mouse hearts, offering an explanation for the rarity of heart cancer.

Cancer cells rely on glutamine but can switch fuels using vitamin B7 (biotin), which acts as a metabolic 'license' via a key enzyme. Without biotin, cancer cells lose this metabolic flexibility and stop growing. Mutations in a cancer-linked gene amplify this vulnerability, offering a potential new therapeutic target.

ThermoCas9, a methylation-sensitive genome-editing enzyme, was characterized in a study published in Nature. The enzyme shows potential for targeting hypomethylated DNA regions in cancer cells, offering new possibilities for precision oncology applications.

Scientists have developed a DNA-based drug that targets cancer cells precisely and can deliver multiple treatments simultaneously, potentially overcoming resistance.